
    
      This is a single arm, open-label Phase I/II study to evaluate the clinical activity of the
      novel inhibitor of Poly(ADP-ribose) polymerase (PARP), ABT-888 with modified FOLFOX-6
      (5-Fluorouracil plus oxaliplatin) in patients with metastatic pancreatic cancer.
    
  